Resonant Capital Advisors LLC Boosts Stock Position in Danaher Co. (NYSE:DHR)

Resonant Capital Advisors LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,652 shares of the conglomerate’s stock after purchasing an additional 75 shares during the period. Resonant Capital Advisors LLC’s holdings in Danaher were worth $3,138,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Wedge Capital Management L L P NC lifted its holdings in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Meridian Financial Partners LLC increased its stake in Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares during the last quarter. Kovack Advisors Inc. increased its stake in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after acquiring an additional 41 shares during the last quarter. Well Done LLC increased its stake in Danaher by 1.2% in the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after acquiring an additional 42 shares during the last quarter. Finally, Waypoint Capital Advisors LLC increased its stake in Danaher by 0.9% in the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after acquiring an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $222.56 on Monday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business has a 50-day simple moving average of $235.40 and a two-hundred day simple moving average of $253.09. The stock has a market cap of $160.75 billion, a price-to-earnings ratio of 42.15, a PEG ratio of 2.80 and a beta of 0.83. Danaher Co. has a 52 week low of $221.34 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm earned $2.09 earnings per share. On average, analysts expect that Danaher Co. will post 7.77 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.49%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on DHR shares. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. JPMorgan Chase & Co. reduced their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Jefferies Financial Group reduced their price target on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Robert W. Baird cut their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Scotiabank began coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.